- Fulcrum lays off majority of staff; Seres extends runway into 2027👥 Fulcrum Therapeutics reduced to a shell: The biotech is letting go 48 of its 57 full-time employees, according to an SEC filing. The step comes after Fulcrum saidEndpoints · 1mo ago↗ source
- Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execUli Stilz has been trotting the globe this year to talk about the future of biotech and bridge an increasingly international industry. He was in Japan this week,Endpoints · 1mo ago↗ source
- Otsuka touts new IgAN evidence as it seeks full approval for VoyxactOtsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune disease that affects the kidneys…